A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

Abstract Background Immune checkpoint blockade has made a significant impact on the clinical outcomes of patients with metastatic urothelial carcinoma (UC). However, evidence for this approach in patients with non‐UC of the urinary tract is limited. Methods This was a phase II open‐label study of du...

Full description

Bibliographic Details
Main Authors: Michal Sarfaty, Karissa Whiting, Min Yuen Teo, Chung‐Han Lee, Vanessa Peters, Jennifer Durocher, Ashley M. Regazzi, Asia S. McCoy, Grace Hettich, Achim A. Jungbluth, Hikmat Al‐Ahmadie, Irina Ostrovnaya, Joshua Chaim, Dean F. Bajorin, Jonathan E. Rosenberg, Gopa Iyer, Samuel A. Funt
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Cancer Medicine
Subjects:
adenocarcinoma
immunotherapy
small cell carcinoma
squamous cell carcinoma
urothelial carcinoma
variant histology
Online Access:https://doi.org/10.1002/cam4.3699

Internet

https://doi.org/10.1002/cam4.3699

Similar Items